Business Description
Medigen Biotechnology Corp
NAICS : 325412
SIC : 2834
ISIN : TW0003176004
Compare
Compare
Traded in other countries / regions
3176.Taiwan IPO Date
2011-11-23Description
Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.58 | |||||
| Equity-to-Asset | 0.19 | |||||
| Debt-to-Equity | 1.83 | |||||
| Debt-to-EBITDA | -2.79 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0.87 | |||||
| Beneish M-Score | -3.14 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 23.3 | |||||
| 3-Year EBITDA Growth Rate | -18.3 | |||||
| 3-Year EPS without NRI Growth Rate | -17.2 | |||||
| 3-Year FCF Growth Rate | 13.1 | |||||
| 3-Year Book Growth Rate | -4.4 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.25 | |||||
| 9-Day RSI | 46.34 | |||||
| 14-Day RSI | 46.31 | |||||
| 6-1 Month Momentum % | -11.73 | |||||
| 12-1 Month Momentum % | 12.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.05 | |||||
| Quick Ratio | 1.86 | |||||
| Cash Ratio | 1.66 | |||||
| Days Inventory | 537.32 | |||||
| Days Sales Outstanding | 50.68 | |||||
| Days Payable | 57.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | -10.19 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 53.32 | |||||
| Operating Margin % | -105.26 | |||||
| Net Margin % | -48.48 | |||||
| FCF Margin % | -47.11 | |||||
| ROE % | -29.47 | |||||
| ROA % | -6.05 | |||||
| ROIC % | -28.48 | |||||
| ROC (Joel Greenblatt) % | -43.25 | |||||
| ROCE % | -16.83 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 594.62 | |||||
| PS Ratio | 4.69 | |||||
| PB Ratio | 3.41 | |||||
| Price-to-Tangible-Book | 3.65 | |||||
| EV-to-EBIT | -3.01 | |||||
| EV-to-EBITDA | -3.53 | |||||
| EV-to-Revenue | 3.18 | |||||
| EV-to-FCF | -6.76 | |||||
| Price-to-Median-PS-Value | 0.29 | |||||
| Earnings Yield (Greenblatt) % | -33.22 | |||||
| FCF Yield % | -10.13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Medigen Biotechnology Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 1,157.72 | ||
| EPS (TTM) (NT$) | -4.031 | ||
| Beta | 0.5 | ||
| Volatility % | 60.72 | ||
| 14-Day RSI | 46.31 | ||
| 14-Day ATR (NT$) | 1.10169 | ||
| 20-Day SMA (NT$) | 39.1725 | ||
| 12-1 Month Momentum % | 12.81 | ||
| 52-Week Range (NT$) | 30.3 - 62.4 | ||
| Shares Outstanding (Mil) | 139.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medigen Biotechnology Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medigen Biotechnology Corp Stock Events
| Event | Date | Price(NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Medigen Biotechnology Corp Frequently Asked Questions
What is Medigen Biotechnology Corp(ROCO:3176)'s stock price today?
The current price of ROCO:3176 is NT$38.95. The 52 week high of ROCO:3176 is NT$62.40 and 52 week low is NT$30.30.
When is next earnings date of Medigen Biotechnology Corp(ROCO:3176)?
The next earnings date of Medigen Biotechnology Corp(ROCO:3176) is .
Does Medigen Biotechnology Corp(ROCO:3176) pay dividends? If so, how much?
Medigen Biotechnology Corp(ROCO:3176) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers